The first stop for professional medicines advice

Zolmitriptan

Published
Topics: Anaesthesia and painNeurological disordersPatent expiries · Safety in BreastfeedingStability in dosette boxesZolmitriptan ·
Contents
  1. dm+d
  2. Medicine Compliance Aid Stability
    1. Zomig · Grunenthal Ltd
    2. Zomig Rapimelt · Grunenthal Ltd
  3. Lactation Safety Information

dm+d

108406003

Medicine Compliance Aid Stability

ZomigGrunenthal Ltd

Grunenthal Ltd
Zomig
Tablets f/c 2.5mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light and moisture.
11 November 2022
Usage of Medicines in Compliance Aids

Zomig RapimeltGrunenthal Ltd

Grunenthal Ltd
Zomig Rapimelt
Orodispersible tablets 2.5mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Orodispersible tablet so unsuitable for MCA
11 November 2022
Usage of Medicines in Compliance Aids

Lactation Safety Information

Caution
Sumatriptan
No published evidence of safety
5HT1-receptor agonist for treatment of acute migraine
Safety in Lactation: Antimigraine drugs
11 August 2020
Bibliography